Keros Therapeutics, Inc. (KROS) stock
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.31+1.28 (+12.76%)
Close on Nov 17, 2026Market cap $224.25MP/E –Yield –
Keros Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Keros Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$47.99M, down 187.2% year over year. For fiscal 2025 it was $107.51M. The highest annual figure on record is $107.51M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $107.51M | – |
| FY2024 | Dec 31, 2024 | -$160.87M | – |
| FY2023 | Dec 31, 2023 | -$124.51M | – |
| FY2022 | Dec 31, 2022 | -$70.06M | – |
| FY2021 | Dec 31, 2021 | -$62.15M | – |
| FY2020 | Dec 31, 2020 | -$36.89M | – |
| FY2019 | Dec 31, 2019 | -$16.00M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$20.42M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.53M | -102.2% |
| Q4 FY2025 | Dec 31, 2025 | -$27.29M | – |
| Q3 FY2025 | Sep 30, 2025 | $3.25M | – |
| Q2 FY2025 | Jun 30, 2025 | -$29.62M | – |
| Q1 FY2025 | Mar 31, 2025 | $161.17M | – |
| Q4 FY2024 | Dec 31, 2024 | -$46.01M | – |
| Q3 FY2024 | Sep 30, 2024 | -$30.50M | – |
| Q2 FY2024 | Jun 30, 2024 | -$39.80M | – |
| Q1 FY2024 | Mar 31, 2024 | -$44.56M | – |
| Q4 FY2023 | Dec 31, 2023 | -$25.46M | – |
| Q3 FY2023 | Sep 30, 2023 | -$33.98M | – |
| Q2 FY2023 | Jun 30, 2023 | -$30.83M | – |
| Q1 FY2023 | Mar 31, 2023 | -$34.24M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.44M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.60M | – |
| Q2 FY2022 | Jun 30, 2022 | -$22.59M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.43M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.57M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.44M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.64M | – |
| Q1 FY2021 | Mar 31, 2021 | -$10.51M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.99M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.86M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.93M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.12M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.50M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.96M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.03M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.51M | – |
See a number that looks wrong?